NCT03289208View on ClinicalTrials.gov

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

April 16, 2018

Study Completion Date

April 20, 2018

Conditions
Renal ImpairmentHealthy
Interventions
DRUG

MCI-186

30 mg of edaravone will be administered intravenously over 60 minutes.

Trial Locations (1)

Unknown

Investigational site, Tokyo

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY